{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Cancer+Recurrent&page=11", "query": { "condition": "Endometrial Cancer Recurrent", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 261, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Cancer+Recurrent&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Cancer+Recurrent&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T16:00:07.833Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02228681", "title": "Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced, Persistent, or Recurrent Endometrial Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Medroxyprogesterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 74, "start_date": "2015-05-21", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 26, "location_summary": "Aurora, Colorado • Miami, Florida • Columbus, Georgia + 21 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Scarborough", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT02228681" }, { "nct_id": "NCT03476798", "title": "Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 49, "start_date": "2018-06-29", "completion_date": "2023-09-29", "has_results": true, "last_update_posted_date": "2024-02-15", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • Oklahoma City, Oklahoma • Charlottesville, Virginia", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03476798" }, { "nct_id": "NCT00063999", "title": "Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Uterine Corpus Carcinoma", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Stage IVA Uterine Corpus Cancer AJCC v7", "Stage IVB Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1381, "start_date": "2003-08-25", "completion_date": "2021-01-05", "has_results": true, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 631, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 408 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00063999" }, { "nct_id": "NCT00250016", "title": "Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Corpus Uteri", "Endometrial Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2003-08", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2023-12-14", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00250016" }, { "nct_id": "NCT05916196", "title": "[18F]FES PET/.CT in Uterine Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Cancer" ], "interventions": [ { "name": "18F-Fluoroestradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2024-04-05", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05916196" }, { "nct_id": "NCT05527184", "title": "First in Human Study of IMGN151 in Recurrent Gynaecological Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial Cancer", "High Grade Serous Adenocarcinoma of Ovary", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Cervical Cancer" ], "interventions": [ { "name": "IMGN151", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 256, "start_date": "2023-01-11", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05527184" }, { "nct_id": "NCT00729586", "title": "Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC1 Uterine Corpus Cancer", "Stage IIIC2 Uterine Corpus Cancer", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Megestrol Acetate", "type": "DRUG" }, { "name": "Tamoxifen Citrate", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 73, "start_date": "2008-09", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 108, "location_summary": "Burbank, California • Palo Alto, California • San Diego, California + 75 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00729586" }, { "nct_id": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Advanced Solid Tumor" ], "interventions": [ { "name": "DB-1303/BNT323", "type": "BIOLOGICAL" }, { "name": "Pertuzumab Injection", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 796, "start_date": "2022-01-31", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 35, "location_summary": "Cerritos, California • Los Angeles, California • San Diego, California + 29 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05150691" }, { "nct_id": "NCT00883116", "title": "A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 551, "start_date": "2009-08", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 28, "location_summary": "Mobile, Alabama • Englewood, Colorado • New Haven, Connecticut + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Englewood", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00883116" }, { "nct_id": "NCT03310567", "title": "A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent/ Metastatic Endometrial Carcinoma" ], "interventions": [ { "name": "Epacadostat + pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-09", "completion_date": "2018-09-10", "has_results": false, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-10-19T16:00:07.833Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310567" } ] }